NASDAQ · GRCE
Healthcare · Biotechnology
$2.10
Down-$0.03 (-1.43%)
Updated Aug 13, 2026, 6:33 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GRCE closed at $2.10 after 21 trading sessions, down 13.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $2.13 | $2.13 | $2.06 | $2.10 | 121.84K |
| Aug 11, 2026 | $2.10 | $2.13 | $2.08 | $2.12 | 97.76K |
| Aug 10, 2026 | $2.13 | $2.16 | $2.075 | $2.11 | 184.32K |
| Aug 7, 2026 | $2.13 | $2.16 | $2.0962 | $2.13 | 120.38K |
| Aug 6, 2026 | $2.14 | $2.25 | $2.08 | $2.12 | 162.7K |
| Aug 5, 2026 | $2.19 | $2.225 | $2.08 | $2.14 | 649.12K |
| Aug 4, 2026 | $2.09 | $2.18 | $2.07 | $2.18 | 100.51K |
| Aug 3, 2026 | $2.13 | $2.14 | $2.08 | $2.08 | 96.02K |
| Jul 31, 2026 | $2.10 | $2.1702 | $2.03 | $2.08 | 177.5K |
| Jul 30, 2026 | $2.04 | $2.08 | $1.95 | $2.07 | 296.91K |
| Jul 29, 2026 | $2.20 | $2.25 | $1.85 | $2.08 | 1.36M |
| Jul 28, 2026 | $2.38 | $2.38 | $2.14 | $2.25 | 517.94K |
| Jul 27, 2026 | $2.30 | $2.4399 | $2.28 | $2.30 | 116.86K |
| Jul 24, 2026 | $2.35 | $2.36 | $2.29 | $2.33 | 127.09K |
| Jul 23, 2026 | $2.36 | $2.3947 | $2.345 | $2.35 | 101.76K |
| Jul 22, 2026 | $2.40 | $2.43 | $2.36 | $2.37 | 104.01K |
| Jul 21, 2026 | $2.43 | $2.475 | $2.41 | $2.43 | 94.31K |
| Jul 20, 2026 | $2.44 | $2.48 | $2.39 | $2.43 | 104.82K |
| Jul 17, 2026 | $2.39 | $2.475 | $2.33 | $2.47 | 122.54K |
| Jul 16, 2026 | $2.43 | $2.50 | $2.335 | $2.41 | 279.8K |
| Jul 15, 2026 | $2.43 | $2.528 | $2.405 | $2.43 | 116.88K |
The latest Smart Investors Daily articles mentioning GRCE.
GRCE research
Company profile and research snapshot.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 24, 2026 | TD Cowen | Buy | — |
| Feb 18, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical DataCompany Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA
Benzinga · Jun 18, 2026
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 160 percent decrease over earnings of $0.10 per share from the
Finnhub · Apr 27, 2026
Corporate Presentation April 2026 Executive Summary GTx-104 | aSAH ...
Benzinga · Apr 24, 2026
TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the price target from $12 to $8.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRCE.
